Investing.com - Catalyst Pharmaceuticals (NASDAQ: CPRX) reported first quarter EPS of $0.310, $0.11 better than the analyst estimate of $0.200. Revenue for the quarter came in at $60.76M versus the consensus estimate of $56.85M.
Guidance
Catalyst Pharmaceuticals sees FY 2023 revenue of $375.000M-$385.000M versus the analyst consensus of $382.700M.
Catalyst Pharmaceuticals's stock price closed at $14.340. It is down -10.380% in the last 3 months and up 81.750% in the last 12 months.
Catalyst Pharmaceuticals saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Catalyst Pharmaceuticals's stock price’s past reactions to earnings here.
According to InvestingPro, Catalyst Pharmaceuticals's Financial Health score is "excellent performance".
Check out Catalyst Pharmaceuticals's recent earnings performance, and Catalyst Pharmaceuticals's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar